Contact Information

Email Sriram Vaidyanathan, PhD

Center for Gene Therapy575 Children’s CrossroadColumbus, OH 43207 (map)

Learn more about Sriram Vaidyanathan

Research

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Biography

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Professional Experience

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

Contact Information

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Connect with Sriram Vaidyanathan

Connect on LinkedIn

Connect on Twitter

Contact Information

Email Sriram Vaidyanathan, PhD

Center for Gene Therapy575 Children’s CrossroadColumbus, OH 43207 (map)

Learn more about Sriram Vaidyanathan

Research

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Biography

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Professional Experience

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

Contact Information

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Connect with Sriram Vaidyanathan

Connect on LinkedIn

Connect on Twitter

Contact Information

Email Sriram Vaidyanathan, PhD

Center for Gene Therapy575 Children’s CrossroadColumbus, OH 43207 (map)

Learn more about Sriram Vaidyanathan

Contact Information

  • Email Sriram Vaidyanathan, PhD
  • Center for Gene Therapy575 Children’s CrossroadColumbus, OH 43207 (map)

Learn more about Sriram Vaidyanathan

Research

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Research

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Research

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases. Publications

                  Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  

                


                  Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.

                


                  Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.

                


                  Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

Lab(s)

Center for Gene Therapy

The discovery of CRISPR/Cas9 has enabled us to precisely correct genetic mutations and to engineer cells with novel functions. Therapies using CRISPR/Cas9 are being tested in clinical trials for the treatment of many diseases including genetic disorders affecting the blood (sickle cell disease, beta-thalassemia) and liver. The application of this technology to treat airway diseases needs further technological development. Cystic fibrosis (CF) is the most common genetic disease affecting the airways. Dr. Vaidyanathan has been working on developing a genome edited airway stem cell therapy approach to treat cystic fibrosis. His previous research demonstrated the high efficiency correction of CF causing mutations in airway stem cells. Clinical application of this technology requires the transplantation of corrected airway stem cells into the airways. His lab will continue to further optimize genome editing in airway stem cells and develop strategies to transplant gene corrected airway stem cells into the airways to treat CF and other airway diseases.

Lab(s)

Center for Gene Therapy

  • Center for Gene Therapy

                    Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;  



                Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.



                Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.



                Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

View More Publications

  • Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med. 2022 Jul 20;
  • Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, Salahudeen AA, Dudek AM, Teran CA, Davis TH, Lee CM, Bao G, Randell SH, Artandi SE, Wine JJ, Kuo CJ, Desai TJ, Nayak JV, Sellers ZM, Porteus MH. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022 Jan 5; 30: 223-237.
  • Vaidyanathan S, Salahudeen AA, Sellers ZM, Bravo DT, Choi SS, Batish A, Le W, Baik R, de la O S, Kaushik MP, Galper N, Lee CM, Teran CA, Yoo JH, Bao G, Chang EH, Patel ZM, Hwang PH, Wine JJ, Milla CE, Desai TJ, Nayak JV, Kuo CJ, Porteus MH. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. Cell Stem Cell. 2020 Feb 6; 26: 161-171.e4.
  • Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7; 12: 530-542.

Biography

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Biography

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Biography

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Sriram Vaidyanathan, PhD, is a principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in Biomedical Engineering from Purdue University and his PhD in Biomedical Engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

  • Center for Gene Therapy
  • Principal Investigator
  • Primary Department
  • Center for Gene Therapy

Awards, Honors & Organizations

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

Awards, Honors & Organizations

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

Awards, Honors & Organizations

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022 Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020 Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019 Member, American Society of Cell and Gene Therapy, 2017 - Present

  • Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2022
  • Meritorious Abstract Travel Award, American Society of Cell and Gene Therapy, 2020
  • Junior Investigator Travel Award, Cystic Fibrosis Foundation Basic Science Conference, 2019
  • Member, American Society of Cell and Gene Therapy, 2017 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Education

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Education

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Date of Appointment at Nationwide Children’s Hospital: 08/01/2022

Post Doctoral

Stanford University

Date Completed: 07/31/2022

Graduate School

University of Michigan

Date Completed: 04/30/2016

Undergraduate School

Purdue University

Date Completed: 12/31/2010

Professional Experience

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

Professional Experience

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

Professional Experience

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

2021 - 2022 Stanford University, Instructor, Department of Pediatrics2016 - 2021 Stanford University, Postdoctoral Scholar, Department of Pediatrics

2021 - 2022 Stanford University, Instructor, Department of Pediatrics

Contact Information

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Contact Information

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Contact Information

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Center for Gene Therapy

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)

Email Sriram Vaidyanathan

                    575 Children's CrossroadColumbus, OH 43207 (map)
  • Email Sriram Vaidyanathan
  • 575 Children’s CrossroadColumbus, OH 43207 (map)

Connect with Sriram Vaidyanathan

Connect on LinkedIn

Connect on Twitter